New insulin biosimilar matches leading drug in diabetes trial
NCT ID NCT05802862
First seen May 05, 2026 · Last updated Jun 12, 2026 · Updated 8 times
Summary
This study tested a new insulin called 22011 against a standard insulin (Ryzodeg) in 414 Chinese adults with type 2 diabetes. The goal was to see if the new insulin works just as well and is as safe. Results showed similar blood sugar control over 26 weeks, offering a potential alternative for managing diabetes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sunshine Lake Pharma Co., Ltd.
Dongguan, Guangdong, 523000, China
Conditions
Explore the condition pages connected to this study.